Mexican Registry of Cardiomyopathies: baseline data, diagnostic strategies, and treatment approaches in Mexico

Guillermo A. Llamas-Esperón, Hospital Cardiológica Aguascalientes, Aguascalientes, Mexico
Enrique A. Berrios-Bárcenas, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México; Hospital Español de México, Ciudad de México; México
Jorge E. Cossío-Aranda, Sociedad Mexicana de Cardiología, Ciudad de México, México
Sylvia Salmun-Nehmad, Instituto Nacional de Cardiología “Ignacio Chávez”, Ciudad de México, México
Rahab A. Morales Flores, Instituto Nacional de Cardiología “Ignacio Chávez”, Ciudad de México, México
Maria C. Escalante-Seyffert, Hospital Español de México, Ciudad de México, Mexico
Jorge Leal-Cavazos, Hospital Cardiológica Aguascalientes, Aguascalientes, México
Eufracino Sandoval-Rodríguez, Hospital Cardiológica Aguascalientes, Aguascalientes, México
Eduardo Pamplona-Ávila, Hospital Cardiológica Aguascalientes, Aguascalientes, México
Enrique Sánchez-Hiza, Hospital Cardiológica Aguascalientes, Aguascalientes, México
Liliana E. Ramos-Villalobos, Hospital Civil de Guadalajara “Juan I Menchaca”, Jalisco, México
Luisa F. Aguilera-Mora, Instituto Cardiovascular de Mínima Invasión, Jalisco, Mexico
Mario A. Benavides-González, Hospital Universitario de la Universidad Autónoma de Nuevo León, Monterrey, México
Carlos D. Carrillo, Hospital Cardiológica Aguascalientes, Aguascalientes, México
Guillermo Llamas-Delgado, Hospital Cardiológica Aguascalientes, Aguascalientes, Mexico
Jonathan H. Zaldívar-Zurita, Hospital Cardiológica Aguascalientes, Aguascalientes, Mexico
Norberto Matadamas-Hernández, Hospital General de Acapulco, Acapulco Guerrero, México; Grupo REMEMI. Mexico

Objectives: The study aimed to know the clinical, demographic, diagnostic, and treatments characteristics in patients with cardiomyopathies in Mexico. Methods: The Mexican Registry of Cardiomyopathies (REMEMI) is an observational, prospective and national study of patients with cardiomyopathies, which includes: Dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM) and arrhythmogenic cardiomyopathy of the right ventricle (ARVC). Results: A total of 1026 patients from most states of the Mexican Republic (19) were included, with 494 corresponding to DCM, 490 to HCM, 35 to RCM, and seven to ARVC. We found significant differences between the various cardiomyopathy phenotypes (p < 0.05) in the coexistence with diabetes, use of implantable defibrillator, presence of ventricular tachycardia, and NYHA functional class ≥ 1. There were no significant differences in age and predominant gender between each one. When analyzing by phenotype, we found that patients with HCM have limited use of diagnostic methods considered indispensable, such as cardiac magnetic resonance, Holter monitoring, and genetic testing in patients and their relatives. Conclusion: Seeking contemporary information through observational registries in Mexico is a valuable opportunity to understand the characteristics of the methods used in the study and treatment of diseases such as cardiomyopathies by Mexican physicians. It can provide information for the implementation of management guidelines and strategies to disseminate findings to improve healthcare in our country.

Keywords: Registry. Cardiomyopathy. Dilated cardiomyopathy. Hypertrophic cardiomyopathy. Restrictive cardiomyopathy. Arrhythmogenic right ventricular cardiomyopathy.